TheStreet’s Jim Cramer discussed the bear market in biotechs while answering viewer questions from social media on Friday. A viewer asked about Regeneron (REGN), and Cramer responded ‘I’m not going to say don’t buy Regeneron, not down here. I like it.’ Cramer also talked about how Celgene (CELG), Biogen (BIIB) and Amgen (AMGN) have all been slammed. Cramer was asked about Oracle (ORCL) and he said the stock is okay, but he likes Salesforce.com (CRM), which is winning business. A viewer wanted to know about Nestle (NSRGY), and Cramer said if the dollar has peaked, it’s not a good long term play. He does like Coca-Cola (KO), which he believes will move much higher. Cramer is portfolio manager of Action Alerts PLUS. Send your questions to Cramer on Facebook or Twitter, use hashtag CramerQ.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.